This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Myriad Genetics Rides on EndoPredict Amid Coronavirus Crisis
by Zacks Equity Research
Myriad Genetics (MYGN) expects to register an uptick in hereditary cancer volumes on account of its contract with UnitedHealthcare.
Myriad Genetics Unveils New Home DNA Sample Collection Kit
by Zacks Equity Research
Myriad Genetics' (MYGN) home DNA sample collection test kit for its GeneSight Psychotropic test enables physicians to remotely provide treatment options to patients with mental health issues.
Myriad Genetics' myPath Melanoma Proved Superior Per New Study
by Zacks Equity Research
Myriad Genetics' (MYGN) myPath Melanoma's accuracy to classify skin lesions, termed as indeterminate by standard pathological review, validated by the latest study.
Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger
by Zacks Equity Research
Zacks.com featured highlights include: Myriad Genetics, Casella Waste, CNH and Schlumberger
4 Toxic Stocks to Disown or Play Short to Book Profits
by Zacks Equity Research
If you are a smart investor and can precisely spot toxic stocks, you may gain by resorting to an investing strategy called short selling.
Myriad Genetics' Prolaris Receives Favorable Coverage Policies
by Zacks Equity Research
Myriad Genetics (MYGN) paves the way for bringing more prostate cancer patients under the purview of Prolaris testing through their health plan.
Myriad Genetics' Test Better Predicts Drug Levels Per Study
by Zacks Equity Research
Myriad Genetics' (MYGN) GeneSight Psychotropic test is shown to be superior at predicting blood concentrations unlike single-gene testing as demonstrated by a latest study.
Keep These 4 Toxic Stocks Off Your Portfolio to Avoid Losses
by Zacks Equity Research
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Why Is Myriad (MYGN) Up 8.9% Since Last Earnings Report?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
by Zacks Equity Research
Zacks.com featured highlights include: Myriad Genetics, Cinemark, Vericel and IDEXX Laboratories
Dump These 4 Toxic Stocks or Sell Short for Timely Profits
by Zacks Equity Research
Identifying toxic stocks and discarding them at the right time is the key to guard your portfolio from big losses.
Myriad's (MYGN) EndoPredict Grows Amid Coronavirus Mayhem
by Zacks Equity Research
Within Molecular Diagnostics, Myriad Genetics (MYGN) registers strong sales for EndoPredict, myChoice CDx and BRACAnalysis CDx.
Biotech ETFs to Gain From Latest Advancements in Cancer Drugs
by Sweta Jaiswal, FRM
The rising incidence of cancer cases has encouraged several major pharmaceutical and biotech players to invest substantially in the developments of drugs.
AstraZeneca's Lynparza Gets FDA Nod for New Ovarian Cancer Use
by Zacks Equity Research
FDA approves AstraZeneca's (AZN) PARP inhibitor Lynparza as a first-line maintenance treatment for HRD-positive advanced ovarian cancer. The approval was based on data from the phase III PAOLA-1 study.
Myriad Genetics (MYGN) Lags Q3 Earnings Estimates, Cancels View
by Zacks Equity Research
Myriad Genetics (MYGN) reports revenue declines in both reporting segments in Q3 resulting from coronavirus-led business disruptions.
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Safeguard Your Portfolio by Abandoning These 4 Toxic Stocks
by Zacks Equity Research
Dump or short sell these four toxic stocks from your portfolio to avoid losses.
Myriad Genetics' (MYGN) BRACAnalysis Gets Japan Reimbursement
by Zacks Equity Research
Myriad Genetics (MYGN) launches BRACAnalysis Diagnostic System in Japan, after receiving reimbursement for the system, which will enable easier identification of HBOC patients.
Myriad Grows Internationally, Hereditary Cancer Revenues Soft
by Zacks Equity Research
Myriad Genetics (MYGN) registers soft Hereditary Cancer, GeneSight, Vectra as well as Prenatal revenues in second-quarter fiscal 2020.
Myriad (MYGN) Down 44.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems
by Zacks Equity Research
Zacks.com featured highlights include: Envestnet, First Majestic Silver, Myriad Genetics, Vericel and Casella Waste Systems
Dump These 5 Toxic Stocks Right Away
by Zacks Equity Research
Accurately identifying toxic stocks and abandoning or short selling those at the right time is the key to safeguard your portfolio from big losses.
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, Myriad Genetics, LabCorp, QIAGEN and Thermo Fisher
Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On
by Sriparna Ghosal
The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.
Steer Clear Of These 5 Toxic Stocks Before It's Too Late
by Zacks Equity Research
Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.